Manufacturer
DUOPHARMA HAPI SDN. BHD.(MALAYSIA)
Registraction Number
MAL14125128AZ
Content:
Each Lebreta tablet contains:
Letrozole: 2.5 mg
Indications:
Breast Cancer: Treatment of hormone receptor-positive breast cancer in postmenopausal women. It can be used as:
Adjuvant treatment (after surgery) for early breast cancer.
Extended adjuvant treatment following standard adjuvant tamoxifen therapy.
First-line treatment for advanced breast cancer.
Treatment for advanced breast cancer after relapse or disease progression.
Instructions:
Dosage: The recommended dose is one tablet once daily.
Administration: Take the tablet with a sufficient amount of fluid (e.g., water). It can be taken with or without food.
Duration: Continue taking Lebreta for as long as your doctor recommends. Do not stop taking it without consulting your doctor.
Malaysia
